trial

A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia

NCTId NCT01451164
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Completed
Enrollment 459 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2015-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Completed
Enrollment
459 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2011-10
Primary completion
2015-06
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Brexpiprazole (Rexulti)

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Investigators

1
Kyoji Imaoka, Operating OfficerStudy Director

Sites

0 total

Linked catalysts

1
A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia — primary completion2015-06

Facts & assertions

4 sourced
Enrollment
459
Phase
PHASE2,PHASE3
Primary Completion Date
2015-06
Status
COMPLETED
relationships
The graph out of here
drug
Brexpiprazole (Rexulti)
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Kyoji Imaoka, Operating Officer
person